Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib DDI Study with Digoxin and Rosuvastatin in Healthy Participants
NCT07855250Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilzabrutinib, sponsored by Sanofi. Primary endpoints: Area Under the Curve, Area Under the Curve from time zero to the last quantifiable concentration and 1 more. Started Oct 2026; status: active, not recruiting.
02
Drugs
rilzabrutinib
Beyond the preview
Go deeper on NCT07855250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855250.